Narsoplimab is a prescription medicine indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). It is available as injection for intravenous use. MedsAcross supplies Narsoplimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Source: US FDA prescribing information
Narsoplimab-wuug inhibits MASP-2, the effector enzyme of the lectin pathway of the complement system, blocking lectin-dependent activation of complement component 3 (C3) and C4 without affecting the classical and alternative pathways of complement. In hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), MASP-2 inhibition is thought to prevent lectin pathway-mediated cellular injury, including endothelial cell injury in small blood vessels.
Source: US FDA prescribing information
Weight (kg) Recommended Dosage Greater than or equal to 50 kg 370 mg given as an intravenous infusion over 30 minutes once weekly. Increase frequency to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms. Less than 50 kg 4 mg/kg given as an intravenous infusion over 30 minutes once weekly. See Full Prescribing Information for instructions on preparation and administration.
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
Serious infections: Monitor patients for signs/symptoms and treat appropriately. Serious Infections Serious and life-threatening infections have occurred in patients treated with YARTEMLEA. Serious infections, independent of causality, were reported in 36% (10/28) of patients with TA-TMA receiving YARTEMLEA in clinical trials. These infections included sepsis, viral infections, pneumonia, bacteremia, fungal infection, gastroenteritis, respiratory tract infection and urosepsis. If YARTEMLEA is administered to patients with active infections, monitor closely for signs and symptoms of worsening infection and treat promptly.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections Most common adverse reactions (incidence > 20% and independent of causality) are viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue and hypokalemia.
Source: US FDA prescribing information
Store YARTEMLEA vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Narsoplimab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Yartemlea 370 mg/2 mL injectionIntravenous Cold chain | Omeros | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 December 2025 | Drugs@FDA |
| EU (EMA) | Opinion | EMA medicines data |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Narsoplimab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Narsoplimab, including Yartemlea.
Yes. The US FDA first approved Narsoplimab on 23 December 2025, according to Drugs@FDA.
At least one listed presentation of Narsoplimab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Narsoplimab is classified under ATC code L01FX (Cancer medicines (antineoplastics), subgroup L01F, subgroup L01FX).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.